IONIS-FXIRx 因子XI反义抑制剂在终末期肾病患者中的2期研究
这项多中心2期研究纳入49例接受血液透析的终末期肾病患者,先以6例开放标签评估300 mg IONIS-FXIRx在透析前后的药代动力学,随后43例双盲随机接受200 mg或300 mg IONIS-FXIRx或安慰剂治疗12周。第85天时,200 mg组、300 mg组和安慰剂组的FXI活性较基线分别平均下降56.0%、70.7%和3.9%,大出血事件分别发生于0例(0.0%)、1例(6.7%)和1例(7.7%),均被认为与治疗无关。
要点
- IONIS-FXIRx 在透析前后注射的药代动力学相似,重复给药后未见蓄积。
- 第85天 FXI 活性较基线平均下降:200 mg组 56.0%,300 mg组 70.7%,安慰剂组 3.9%。
- 大出血事件发生于200 mg组0例(0.0%)、300 mg组1例(6.7%)、安慰剂组1例(7.7%),均与治疗无关。
核心结论
- IONIS-FXIRx 降低了接受血液透析的终末期肾病患者的FXI活性。
- 需要进一步研究以确定FXI作为需要血液透析患者的治疗靶点的获益-风险特征。
研究设计与样本
- 多中心2期研究,共纳入49例接受血液透析的终末期肾病患者,分两部分进行。
- 药代动力学队列6例接受开放标签300 mg IONIS-FXIRx,分别在血液透析前和透析后给药。
- 随后43例以双盲、随机设计接受200 mg或300 mg IONIS-FXIRx或安慰剂治疗12周。
- 评估IONIS-FXIRx的药代动力学、药效动力学和不良事件(ClinicalTrials.gov: NCT02553889)。
主要发现
- IONIS-FXIRx的药代动力学与既往研究一致,透析前或透析后注射相似。
- 重复给药后未观察到IONIS-FXIRx蓄积。
- 第85天时,FXI活性平均值较基线下降:200 mg组56.0%,300 mg组70.7%,安慰剂组3.9%。
- FXI抗原水平与FXI活性平行变化。
- 观察到活化部分凝血活酶时间(aPTT)呈剂量依赖性延长,国际标准化比值(INR)无变化。
关键数值与推荐
- 药代动力学队列6例接受单次开放标签300 mg IONIS-FXIRx,分别在血液透析前和透析后给药。
- 随机阶段43例接受200 mg或300 mg IONIS-FXIRx或安慰剂治疗12周。
- 第85天FXI活性较基线平均下降:200 mg组56.0%,300 mg组70.7%,安慰剂组3.9%。
- 大出血事件:200 mg组0例(0.0%),300 mg组1例(6.7%),安慰剂组1例(7.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定FXI作为需要血液透析患者的治疗靶点的获益-风险特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIRx is a novel strategy that may safely reduce the risk of thrombotic events. METHODS: This multicenter study enrolled 49 patients receiving HD in 2 parts. First, 6 participants (pharmacokinetics [PK] cohort) received 1 open-label 300 mg dose of IONIS-FXIRx both before and after HD. Subsequently, 43 participants were treated in a double-blind, randomized design with 200 mg or 300 mg IONIS-FXIRx or placebo for 12 weeks. The PK, pharmacodynamics (PD), and adverse events of IONIS-FXIRx were evaluated (ClinicalTrials.gov: NCT02553889). RESULTS: The PK of IONIS-FXIRx was consistent with previous studies and similar whether injected before or after HD. No accumulation of IONIS-FXIRx was observed after repeat administration. By day 85, mean levels of FXI activity fell 56.0% in the 200 mg group, 70.7% in the 300 mg group, and 3.9% in the placebo group compared with baseline. FXI antigen levels paralleled FXI activity. Dose-dependent prolongation of activated partial thromboplastin time (aPTT) was observed, with no changes in international normalized ratio (INR). IONIS-FXIRx was not associated with drug-related serious adverse events. In the randomized phase of the study, major bleeding events occurred in 0 (0.0%; 200 mg), 1 (6.7%; 300 mg), and 1 (7.7%; placebo) patients and were not considered related to treatment. CONCLUSION: IONIS-FXIRx reduced FXI activity in patients with ESRD receiving HD. Further studies are needed to determine the benefit-risk profile of FXI as a therapeutic target for patients who require HD.
引用
- Walsh M, Bethune C, Smyth A, et al. Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney Int Rep. 2021. PMID: 35155859. doi:10.1016/j.ekir.2021.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。